News
PRQR
2.200
+2.80%
0.060
Weekly Report: what happened at PRQR last week (0630-0704)?
Weekly Report · 1d ago
Weekly Report: what happened at PRQR last week (0623-0627)?
Weekly Report · 06/30 11:55
ProQR Therapeutics Price Target Maintained With a $8.00/Share by Cantor Fitzgerald
Dow Jones · 06/27 12:50
Citizens JMP Reaffirms Their Buy Rating on ProQR (PRQR)
TipRanks · 06/27 12:45
Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target
Benzinga · 06/27 12:40
Cantor Fitzgerald Remains a Buy on ProQR (PRQR)
TipRanks · 06/27 12:07
ProQR Submits CTA for Phase 1 Study of AX-0810
TipRanks · 06/26 21:01
PROQR ANNOUNCES CTA SUBMISSION FOR PHASE 1 STUDY OF AX-0810 TARGETING NTCP
Reuters · 06/26 20:30
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
Barchart · 06/26 15:30
Weekly Report: what happened at PRQR last week (0616-0620)?
Weekly Report · 06/23 11:46
Weekly Report: what happened at PRQR last week (0609-0613)?
Weekly Report · 06/16 11:55
Weekly Report: what happened at PRQR last week (0602-0606)?
Weekly Report · 06/09 11:56
ProQR Shareholders Approve Key Resolutions at Annual Meeting
TipRanks · 06/03 20:27
abrdn World Healthcare Fund Q1 2025 Commentary
Seeking Alpha · 06/03 12:20
ProQR Therapeutics Reports Q1 2025 Financial Results
TipRanks · 06/03 03:51
Weekly Report: what happened at PRQR last week (0526-0530)?
Weekly Report · 06/02 12:07
Weekly Report: what happened at PRQR last week (0519-0523)?
Weekly Report · 05/26 12:06
Weekly Report: what happened at PRQR last week (0512-0516)?
Weekly Report · 05/19 11:54
ProQR Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 05/13 17:59
ProQR Therapeutics Price Target Cut to $9.00/Share From $15.00 by Oppenheimer
Dow Jones · 05/13 17:59
More
Webull provides a variety of real-time PRQR stock news. You can receive the latest news about Proqr Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About PRQR
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).